Price$99.08+1.18 (+1.21%)
01:30 PM07:45 PM
News · 26 weeks54-10%
2026-03-152026-09-06
Mix4390d
- Insider30(70%)
- SEC Filings5(12%)
- Other4(9%)
- Earnings2(5%)
- Leadership1(2%)
- Analyst1(2%)
Latest news
25 items- INSIDERChief Technology Officer Tsao David converted options into 20,000 shares and gifted 20,000 shares (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- SECSEC Form 144 filed by BillionToOne Inc.144 - BillionToOne, Inc. (0002070849) (Subject)
- PRBillionToOne to Participate in the Wells Fargo 21st Annual Healthcare ConferenceMENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo 21st Annual Healthcare Conference. Management will participate in a fireside chat from 2:15pm to 2:50pm Eastern Time on Wednesday, September 9, 2026.A live and archived webcast will be available on the "Events & Presentations" page of BillionToOne's investor relations website at https://investors.billiontoone.com/news-events/events-presentation
- ANALYSTCanaccord Genuity initiated coverage on BillionToOne with a new price targetCanaccord Genuity initiated coverage of BillionToOne with a rating of Buy and set a new price target of $120.00
- PRBillionToOne Launches Northstar Origin, a New Liquid Biopsy Test to Help Identify Tissue of OriginNew add-on test from a single blood draw; BillionToOne also expands Northstar Select® panel to 102 genesMENLO PARK, Calif., Sept. 1, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar Origin™, a new liquid biopsy add-on test for tissue-of-origin prediction, along with the expansion of its Northstar Select® panel from 84 to 102 genes to cover genes that are included in recent and upcoming FDA approvals. Northstar Origin is a physician-ordered add-on test to N
- INSIDERDirector Kolluri Krishna Kittu disposed of 484,442 shares and acquired 78,244 shares (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $141,700 worth of shares (1,417 units at $100.00) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 26,467 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David exercised 10,000 shares at a strike of $2.80 and sold $1,000,000 worth of shares (10,000 units at $100.00) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- PRLargest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive ConditionsStudy of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA resultsMENLO PARK, Calif., Aug. 18, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green Journal. This is the first prospective NIPT study conducted in an intended-use screening population wit
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $131,583 worth of shares (1,417 units at $92.86) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 27,884 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David exercised 10,000 shares at a strike of $2.80 and sold $928,600 worth of shares (10,000 units at $92.86) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChairman and CEO Atay Oguzhan exercised 15,539 shares at a strike of $2.80 and sold $2,331,352 worth of shares (15,539 units at $150.03) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChairman and CEO Atay Oguzhan exercised 32,500 shares at a strike of $2.80 and sold $6,167,960 worth of shares (45,000 units at $137.07) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- SECSEC Form 10-Q filed by BillionToOne Inc.10-Q - BillionToOne, Inc. (0002070849) (Filer)
- SECBillionToOne Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BillionToOne, Inc. (0002070849) (Filer)
- PRBillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue GuidanceMENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026. Financial Highlights: Total revenue of $109.4 million in the second quarter of 2026, compared to $66.6 million in the second quarter of 2025, an increase of 64%.Prenatal clinical testing revenue was $94.2 million in the second quarter of 2026, an increase of 55% from the second quarter of 2025.Oncology clinical testing revenue was $13.7 million in the
- INSIDERChief Product Officer Sakakibara Shan Riku sold $560,840 worth of shares (4,000 units at $140.21) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 200,000 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDEROfficer Johnson Nancy Joann sold $1,821,628 worth of shares (14,199 units at $128.29) as part of a pre-agreed trading plan, decreasing direct ownership by 67% to 6,900 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- PRBillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for NorthstarRenowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne to advance Northstar's role in guiding real treatment decisionsMENLO PARK, Calif., July 20, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Ethan Dmitrovsky, MD, one of the most accomplished and influential physician leaders in oncology, as Chief Medical Officer, Oncology. Dr. Dmitrovsky will lead medical strategy for BillionToOne's Northstar liquid biopsy portfolio
- INSIDERSVP of Laboratory Operations Ten Bosch John Roderick sold $533,330 worth of shares (4,251 units at $125.46) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 29,301 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Technology Officer Tsao David exercised 20,000 shares at a strike of $2.80 and sold $2,497,698 worth of shares (20,000 units at $124.88) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- PRBillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ:BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day. Analysts planning to participate in the conference call should register here before the 1:30pm Pacific Time / 4:30pm Eastern Time start. A live and archived webcast for interested
- INSIDERChairman and CEO Atay Oguzhan exercised 12,500 shares at a strike of $2.80 and sold $1,576,276 worth of shares (12,500 units at $126.10) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChief Product Officer Sakakibara Shan Riku exercised 4,000 shares at a strike of $29.82 and sold $1,000,000 worth of shares (8,000 units at $125.00) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 204,000 units (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
- INSIDERChairman and CEO Atay Oguzhan exercised 26,250 shares at a strike of $2.80 and sold $4,729,379 worth of shares (38,750 units at $122.05) as part of a pre-agreed trading plan (SEC Form 4)4 - BillionToOne, Inc. (0002070849) (Issuer)
BLLN FAQ
6 questionsWhere does BLLN stock trade?
BillionToOne Inc. (BLLN) is listed on NASDAQ.What sector and industry is BLLN in?
BillionToOne Inc. operates in the Health Care sector, Medical Specialities industry.When did BillionToOne Inc. go public?
BillionToOne Inc. (BLLN) completed its IPO in 2025.What are analysts saying about BLLN?
BillionToOne Inc. has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-09-02.What companies are similar to BLLN?
Notable peers in the same industry include UNH (UnitedHealth Group Incorporated), ANTM (Anthem Inc.), ELV (Elevance Health Inc.), CI (The Cigna Group), HUM (Humana Inc.). Compare BLLN side-by-side with any of them on Quantisnow.How can I track BLLN on Quantisnow?
Quantisnow aggregates BillionToOne Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BLLN to receive live email and push alerts on every new disclosure.